Show simple item record

dc.contributor.advisorChowdhury, Namara Mariam
dc.contributor.authorChoki, Kinley
dc.date.accessioned2024-10-03T06:56:54Z
dc.date.available2024-10-03T06:56:54Z
dc.date.copyright©2024
dc.date.issued2024-07
dc.identifier.otherID 20346072
dc.identifier.urihttp://hdl.handle.net/10361/24298
dc.descriptionThis thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2024.en_US
dc.descriptionCataloged from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 35-36).
dc.description.abstractAcute lymphoblastic Leukemia has currently about 6,550 new cases from which about 3,590 are male and about 2,960 are females. ALL occurs in fewer than half of 1% of all cancer in the US. There are multiple subtypes of ALL out of which there are two main types and only in some cases it can be cured. Treatment of different types are available for the acute lymphoblastic Leukemia (ALL). Some treatments are in the ongoing trials and some are standard treatments that are currently used. Blinatumomab is a bispecific monoclonal antibody approved by the US, FDA for the treatment in patients with relapsed or refractory B-cell precursor of ALL on the basis of phase 3 clinical trials that shows the efficacy and some manageable toxic effects. It shows superior overall survival as compared to standard chemotherapy. The refractory or relapsed acute lymphoblastic Leukemia (ALL) patients, when treated with the allogeneic stem cell transplantation and cytotoxic chemotherapy have poor prognosis or the pitiful rate of survival approximately 5%. In this review, the clinical trial data of blinatumomab is analysed, an evaluation of its effectiveness and safety in comparison to the chemotherapy is provided, which can be used to unfold the full potential of this drug in the future.en_US
dc.description.statementofresponsibilityKinley Choki
dc.format.extent48 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectAcute lymphoblastic leukemiaen_US
dc.subjectLeukemiaen_US
dc.subjectR/R B-cell precursor ALLen_US
dc.subjectFDAen_US
dc.subjectBlood canceren_US
dc.subject.lcshLymphoblastic leukemia.
dc.subject.lcshCancer--Immunotherapy.
dc.subject.lcshMonoclonal antibodies--Therapeutic use.
dc.titleA review on bispecific antibody (blinatumomab) for the treatment of acute lymphoblastic leukemiaen_US
dc.typeThesisen_US
dc.contributor.departmentDepartment of Pharmacy, Brac University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record